GT Biopharma to Participate in the 38th Annual Roth Conference

Core Insights - GT Biopharma, Inc. is a clinical stage immuno-oncology company focused on developing therapeutics based on its proprietary TriKE NK cell engager platform [1][3] - Michael Breen, the Executive Chairman and CEO, will participate in the 38th Annual Roth Conference from March 22-24, 2026 [1][2] Company Overview - GT Biopharma specializes in the development and commercialization of immuno-oncology therapeutic products utilizing the TriKE NK cell engager platform, which enhances the cancer-killing abilities of natural killer cells [3] - The company holds an exclusive worldwide license agreement with the University of Minnesota for the further development and commercialization of therapies using TriKE technology [3]